Biotech & Genomic Medicine▲
Biotech Stocks Hit 52-Week Highs on Earnings and Pipeline Updates
Several biotech stocks reached 52-week highs on August 11, 2026, driven by quarterly reports and regulatory progress. Alamar Biosciences surged over 30% to $38.54 after reporting second-quarter revenue of $29.43 million and projecting full-year 2026 revenue between $116 million and $120 million. Dyne Therapeutics rose to $27.13 following FDA acceptance of its Biologics License Application for Z-Rostudirsen, with a decision expected in January 2027. Cullinan Therapeutics gained over 7% to $19.82 after narrowing its quarterly loss and announcing plans for Phase 2 trials in autoimmune diseases. Cardinal Health climbed to $258.30 on fiscal 2026 revenue of $254.2 billion and net earnings of $1.7 billion. DexCom reached $89.56 after reporting 13% second-quarter revenue growth to $1.31 billion and forecasting full-year revenue of $5.18 billion to $5.25 billion.
RTTNews·15dRead more ▾
DYN▼
Dyne Therapeutics reports Q2 GAAP EPS of -$1.08, missing estimates by $0.33
Dyne Therapeutics reported a second-quarter GAAP loss of $1.08 per share, missing analyst estimates by $0.33. The company held cash, cash equivalents, and marketable securities of $898.5 million as of June 30, 2026. In July 2026, Dyne completed an underwritten public offering of 21,045,000 shares of common stock, generating estimated net proceeds of approximately $405.0 million. Management expects that its June 30 cash position combined with the offering proceeds will be sufficient to fund operations into the second quarter of 2028.
Seeking Alpha·28dRead more ▾
Biotech & Genomic Medicine▲
Dyne Therapeutics Gets FDA Clearance for DYNE-302 IND in FSHD
Dyne Therapeutics has received U.S. FDA clearance for its investigational new drug application to begin a Phase 1 trial of DYNE-302 in facioscapulohumeral muscular dystrophy. DYNE-302 is the company's third program to enter clinical development using its FORCE platform, which also underpins its Duchenne muscular dystrophy and myotonic dystrophy type 1 candidates. The Phase 1 trial will be a randomized, placebo-controlled, double-blind, multiple ascending dose study in ambulatory adults with FSHD, with safety and tolerability as the primary endpoint. In the first cohort, nine participants will receive three intravenous doses every four weeks, randomized two-to-one to DYNE-302 at 1.5 milligrams per kilogram or placebo. Dyne intends to pursue a traditional approval pathway in the U.S. for DYNE-302, which is designed to suppress DUX4 expression using a TfR1-targeting Fab and siRNA payload.
GlobeNewswire·29dRead more ▾
Dyne Therapeutics grants inducement equity awards to 12 new employees
Dyne Therapeutics has granted inducement equity awards to 12 newly hired employees under Nasdaq Listing Rule 5635(c)(4). The awards consist of non-statutory stock options to purchase up to an aggregate of 358,600 shares of common stock at an exercise price equal to the July 21, 2026 closing price, and restricted stock units covering an aggregate of 116,500 shares. The stock options have a ten-year term and vest over four years, with 25% after one year and the remainder in 12 quarterly installments, while the restricted stock units vest in four equal annual installments, both subject to continued service. The grants were made under Dyne’s 2024 Inducement Stock Incentive Plan.
GlobeNewswire·33dRead more ▾
Dyne Therapeutics shares drop after pricing $375 million public offering
Dyne Therapeutics shares fell 9% on Wednesday after the biotechnology company priced a public offering of common stock expected to raise approximately $375 million. The offering was priced at $20.50 per share, a discount of about 14% to Tuesday's closing price of $23.83. Dyne priced an upsized offering of 18.3 million shares, with gross proceeds estimated at $375.15 million before underwriting discounts and expenses. The company also granted underwriters a 30-day option to purchase up to an additional 2.745 million shares. Morgan Stanley, Jefferies, Evercore ISI, LifeSci Capital and Raymond James are joint book-running managers, with Jones as lead manager. The offering is expected to close on or around July 23, 2026.
Yahoo Finance·35dRead more ▾
Biotech & Genomic Medicine▲impact 4
FDA Accepts Dyne Therapeutics' BLA for Z-Rostudirsen in Duchenne Muscular Dystrophy with Priority Review
The U.S. Food and Drug Administration has accepted Dyne Therapeutics' Biologics License Application for z-rostudirsen, granting Priority Review and setting a target action date of January 21, 2027. The application seeks Accelerated Approval for the treatment of Duchenne muscular dystrophy amenable to exon 51 skipping, based on dystrophin as a surrogate endpoint. In the registrational expansion cohort of the DELIVER trial, treatment with z-rostudirsen once every four weeks led to a robust and statistically significant increase in dystrophin production, with functional improvement observed across multiple clinical endpoints and a favorable safety profile. Dyne expects a potential U.S. launch in the first quarter of 2027 if approval is received on the anticipated timeline. The company is also advancing four other development candidates targeting exons 53, 45, 44, and 55 for DMD.
GlobeNewswire·37dRead more ▾
Biotech & Genomic Medicine▲
TD Cowen Initiates Dyne Therapeutics With Buy Rating on Force Platform Potential
TD Cowen initiated coverage of Dyne Therapeutics with a Buy rating on June 26, citing the potential of its Force platform to improve drug delivery in neuromuscular and CNS diseases. The firm highlighted late-stage candidates z-basivarsen for myotonic dystrophy type 1 and z-rostudirsen for exon 51 Duchenne muscular dystrophy mutations as potential top-tier therapies. Separately, Dyne amended its non-dilutive senior secured term loan with Hercules Capital on June 17, receiving $50 million at closing and gaining the option to draw an additional $50 million tranche upon achieving certain milestones, while the final facility was expanded by $25 million to provide up to $125 million in capital at Hercules' discretion.
Insider Monkey·42dRead more ▾
DYN▲
Dyne Therapeutics edges out Recursion Pharmaceuticals as the preferred speculative biotech buy for 2026
Dyne Therapeutics gets the nod over Recursion Pharmaceuticals as the better buy among development-stage pharma stocks in 2026, according to an analysis by The Motley Fool. Dyne, with a $3.7 billion market cap and no revenue, is preparing its first Duchenne muscular dystrophy treatment for a potential market entry in early fiscal 2027, with a second product expected in 2028, and analysts project sales could surpass $1 billion by 2030. Recursion, a $2 billion market cap company, generated $74.7 million in fiscal 2025 revenue from partnerships but saw a net loss of nearly $645 million, and its own product revenue is seen as years away despite a recent clinical proof of concept for its REC-4881 treatment. Both companies carry high risk, but Dyne appears closer to bringing a treatment to market.
The Motley Fool·53dRead more ▾
DYN▼
Vertex Pharmaceuticals edges out Dyne Therapeutics as the better biotech buy for 2026
Vertex Pharmaceuticals is favored over Dyne Therapeutics as the better drug innovator stock for 2026, according to an analysis by The Motley Fool. Dyne Therapeutics is a clinical-stage company with no revenue, reporting a net loss of $446.2 million in fiscal 2025, while Vertex posted $12 billion in revenue and nearly $4 billion in net income. Vertex's cystic fibrosis portfolio now covers 95% of U.S. patients and is expanding globally, with a promising pipeline including povetacicept for IgA nephropathy. Dyne's first product for Duchenne muscular dystrophy is expected in early fiscal 2027, with analysts projecting $53 million in sales that year and over $1 billion by 2030. Despite Dyne's growth potential, Vertex's strong profitability, heavy R&D investment, and reasonable forward price-to-earnings ratio make it the preferred choice.
The Motley Fool·56dRead more ▾
Viking Therapeutics favored over Dyne Therapeutics for 2026 healthcare investment
The Motley Fool selects Viking Therapeutics over Dyne Therapeutics as the better healthcare stock for 2026, citing the massive obesity-treatment market opportunity for Viking's weight-loss candidate VK2735. Both clinical-stage biotechs reported zero revenue and widening net losses in fiscal 2025, with Dyne posting a loss of nearly $446.2 million and Viking close to $359.6 million. Viking carries no debt and holds a current ratio of roughly 9.3x, while Dyne has a debt-to-equity ratio of 0.19x and a current ratio of approximately 22.3x. The analysis notes Dyne's focus on rare neuromuscular diseases limits its market size, whereas Viking's phase 3 obesity program targets a far larger patient population despite competition from Eli Lilly and Novo Nordisk. Viking also faces an investigation into potential securities-law violations and relies on a license agreement with Ligand Pharmaceuticals.
The Motley Fool·61dRead more ▾
DYN▲
Dyne Therapeutics Appoints Barry Greene to Board of Directors
Dyne Therapeutics has appointed Barry Greene to its Board of Directors. Greene brings more than 30 years of biopharmaceutical experience, with expertise in rare diseases, neuroscience, and oncology. He currently serves as lead independent director at Karyopharm Therapeutics and previously was CEO of Sage Therapeutics from December 2020 to July 2025. Before that, he spent 20 years at Alnylam Pharmaceuticals, most recently as President and COO. Dyne shares closed Monday at $20.87, up 5.40%.
RTTNews·65dRead more ▾
Dyne Therapeutics Grants Inducement Equity Awards to Six New Employees
Dyne Therapeutics has granted inducement equity awards to six newly hired employees under Nasdaq Listing Rule 5635(c)(4). The awards consist of non-statutory stock options to purchase up to an aggregate of 126,000 shares of common stock at an exercise price equal to the June 16, 2026 closing price, and restricted stock units covering an aggregate of 40,100 shares. The stock options have a ten-year term and vest over four years, with 25% vesting on the first anniversary and the remainder in 12 equal quarterly installments. The restricted stock units vest over four years in four equal annual installments, subject to continued service.
GlobeNewswire·69dRead more ▾
Biotech & Genomic Medicine▲
Dyne Therapeutics expands debt facility with Hercules Capital to up to $400 million
Dyne Therapeutics has amended its senior secured term loan facility with Hercules Capital, increasing total borrowing capacity to up to $400 million. The amendment provides an additional $125 million in potential funding, with $50 million drawn immediately at closing. A new $50 million tranche is available at Dyne's option upon achieving certain milestones, and the final tranche was increased by $25 million to up to $75 million, fundable at Dyne's request and Hercules' discretion. Including the $50 million just funded, Dyne has borrowed $200 million across three tranches and retains access to up to $200 million in future funding. The company plans to use the capital to advance its lead candidates, zeleciment rostudirsen for Duchenne muscular dystrophy and zeleciment basivarsen for myotonic dystrophy type 1, toward potential U.S. launches in the next two years.
GlobeNewswire·70dRead more ▾